✦ LIBER ✦

Clinical Trials of Bispecific Antibody MDX-210 in Women with Advanced Breast or Ovarian Cancer that Overexpresses HER-2/neu

✍ Scribed by VALONE, FRANK H.; KAUFMAN, PETER A.; GUYRE, PAUL M.; LEWIS, LIONEL D.; MEMOLI, VINCENT; ERNSTOFF, MARC S.; WELLS, WENDY; BARTH, RICHARD; DEO, YASHWANT; FISHER, JAN; PHIPPS, KATHY; GRAZIANO, ROBERT; MEYER, LOUISE; MROZEK-ORLOWSKI, MARY; WARDWELL, KATHLEEN; GUYRE, VERONICA; MORLEY, THERESA L.; ARVIZU, CHRISTINE; WALLACE, PAUL; FANGER, MICHAEL W.

Book ID: 125543473
Publisher: Mary Ann Liebert
Year: 1995
Tongue: English
Weight: 631 KB
Volume: 4
Category: Article
ISSN: 1061-6128
DOI: 10.1089/scd.1.1995.4.471

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I study of a HER2/neu bispecific

A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu

✍ V. Pullarkat; Y. Deo; J. Link; L. Spears; V. Marty; R. Curnow; S. Groshen; C. Ge 📂 Article 📅 1999 🏛 Springer-Verlag 🌐 English ⚖ 365 KB

Phase I clinical trial of the bispecific

Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer

✍ Repp, R; van Ojik, H H; Valerius, T; Groenewegen, G; Wieland, G; Oetzel, C; Stoc 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 197 KB

Pharmacokinetic–pharmacodynamic relation

Pharmacokinetic–pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neu

✍ Lionel D Lewis; Bernard F Cole; Paul K Wallace; Jan L Fisher; Mary Waugh; Paul M 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 285 KB

Clinical evaluation of the bispecific an

Clinical evaluation of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (Filgrastim) for treatment of advanced breast cancer

✍ H. H. van Ojik; R. Repp; Gerard Groenewegen; Thomas Valerius; Jan G. J. van de W 📂 Article 📅 1997 🏛 Springer-Verlag 🌐 English ⚖ 332 KB

676 - Bispeciffic antibody MDX210 (FcγRI

676 - Bispeciffic antibody MDX210 (FcγRI × HER-2/neu) in combination with G-CSF: Results of a phase I trial in patients with metastatic breast cancer

✍ Th. Valerius; B. Stockmeyer; R. Repp; Y. Deo; H. van Oijk; J.G. van de Winkel; J 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 246 KB

Phase I trial of MDXH210 (FeγRI×HER-2/ne

Phase I trial of MDXH210 (FeγRI×HER-2/neu, bispecific antibody) in combination with G-CSF in patients with metastatic breast cancer: H. van Ojik1, G. Groenewegen1, R. Repp3, T. Valerius3, A. van Oers2, N.A.C. Westerdaal2, Y. Deo4, G.H. Blijham1, J.G.J. van de Winkel2. Departments of Internal Medicine1 and Immunology2, University Hospital, Utrecht, Netherlands, Department of Medicine III, University of Erlangen-Nurnberg3, with Germany, support from Medarex4, Annandale, NJ, USA

📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 110 KB